{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:47:10Z","timestamp":1787075230169,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jmoldx.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:17:29Z","timestamp":1730953049000},"page":"42-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of Molecular Testing for Suspected Myeloproliferative Neoplasm at a Hybrid Community-Academic Health System"],"prefix":"10.1016","volume":"27","author":[{"given":"Andrew B.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cade","family":"Arries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-0010","authenticated-orcid":false,"given":"Andrew C.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Thyagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Yohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3838-4743","authenticated-orcid":false,"given":"Pawel","family":"Mroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2024.10.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib3","first-page":"295","article-title":"Physician use of genetic testing for cancer susceptibility: results of a national survey","volume":"12","author":"Wideroff","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib4","series-title":"Haematolymphoid Tumours: WHO Classification of Tumours, 5th Edition, Volume 11","year":"2024"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41375-022-01781-0","article-title":"CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response","volume":"37","author":"Jutzi","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1472-6963-9-131","article-title":"Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing","volume":"9","author":"Miller","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju256","article-title":"Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers","volume":"106","author":"Schink","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ejhg.2013.158","article-title":"Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care","volume":"22","author":"Miller","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2013.52.4298","article-title":"Physicians' attitudes about multiplex tumor genomic testing","volume":"32","author":"Gray","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/gim.2015.207","article-title":"Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study","volume":"18","author":"Gray","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/cncr.30581","article-title":"Integrating next-generation sequencing into pediatric oncology practice: an assessment of physician confidence and understanding of clinical genomics","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.22094","article-title":"Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia","volume":"86","author":"Peterson","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pathol.2021.01.003","article-title":"Myeloid somatic mutation panel testing in myeloproliferative neoplasms","volume":"53","author":"Ross","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jmoldx.2011.05.007","article-title":"Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology","volume":"13","author":"Tefferi","year":"2011","journal-title":"J Mol Diagn"},{"issue":"Suppl 1","key":"10.1016\/j.jmoldx.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ijlh.13005","article-title":"Myeloproliferative neoplasms: diagnostic workup of the cythemic patient","volume":"41","author":"Wong","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/jclinpath-2012-201008","article-title":"Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm","volume":"65","author":"Langabeer","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jmoldx.2023.09.012","article-title":"Clinical utility and reimbursement of next-generation sequencing-based testing for myeloid malignancies","volume":"26","author":"Soderquist","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.21037\/atm.2018.05.07","article-title":"Optimization of a microfluidics-based next generation sequencing assay for clinical oncology diagnostics","volume":"6","author":"Henzler","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13073-015-0251-2","article-title":"ScanIndel: a hybrid framework for indel detection via gapped alignment, split reads and de novo assembly","volume":"7","author":"Yang","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006007","article-title":"Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling","volume":"7","author":"Oltvai","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2634853520978210","article-title":"The essential thrombocythemia in 2020: what we know and where we still have to dig deep","volume":"13","author":"Accurso","year":"2020","journal-title":"Clin Med Insights Blood Disord"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jclinpath-2018-205527","article-title":"JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing","volume":"72","author":"Mahe","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11845-019-02100-w","article-title":"A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms","volume":"189","author":"Catherwood","year":"2020","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41598-020-80459-y","article-title":"Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera","volume":"11","author":"Piris-Villaespesa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s11606-022-07963-x","article-title":"A rational approach to JAK2 mutation testing in patients with elevated hemoglobin: results from the JAK2 Prediction Cohort (JAKPOT) Study","volume":"38","author":"Chin-Yee","year":"2023","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/cancers12082194","article-title":"Next generation sequencing in MPNs. lessons from the past and prospects for use as predictors of prognosis and treatment responses","volume":"12","author":"Skov","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100708","article-title":"Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice","volume":"42","author":"Lee","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2019.229039","article-title":"Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?","volume":"104","author":"Hasselbalch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ajcp\/aqw131","article-title":"Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian MPN group","volume":"146","author":"Busque","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3324\/haematol.2018.213108","article-title":"Distinguishing essential thrombocythemia JAK2 V617F from polycythemia vera: limitations of erythrocyte values","volume":"104","author":"Silver","year":"2019","journal-title":"Haematologica"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515782400271X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515782400271X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:05:59Z","timestamp":1767229559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152515782400271X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S152515782400271X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.10.003","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Molecular Testing for Suspected Myeloproliferative Neoplasm at a Hybrid Community-Academic Health System","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}